Pasithea Therapeutics Corp.

Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
Investing News Network · 23 Oct 2026
Pasithea at Chardan conference: early nf1 data, safety focus By Investing.com
Investing.com India · 20 Oct 2026
Pasithea Therapeutics (KTTA) Slips 3.40% to $0.41 as Micro-Cap Biotech Holds Near Support - Call Flow Alert
https://www.dars.gov.et/ · 15 Oct 2026
Pasithea Therapeutics (KTTA) Slips 3.40% to $0.41 as Micro-Cap Biotech Holds Near Support - Aggressive Growth Picks
https://www.siam.in/ · 15 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.